AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01815073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Study NCT01815073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: live attenuated JE vaccine
Study NCT02779543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
Study NCT02779543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jawbone UP
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
Study NCT02779543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microsoft Band
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
Study NCT02566278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper airway collapsibility (Pcrit)
Description: To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
Study NCT00235079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
Study NCT00235079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02027740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: almond
Study NCT01337973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT
Description: Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
Study NCT01337973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT+CC
Description: Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
Study NCT01337973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-TAU
Description: Enhanced Treatment as Usual
Study NCT04456452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion, administered by intravenous infusion
Study NCT04456452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care
Study NCT04456452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study NCT03256045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT03256045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemosensitivity Assay
Description: Undergo in vitro chemosensitivity testing
Study NCT03256045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03256045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03256045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study NCT02298933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: 300 mg single-use vials
Study NCT02146287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycled Light
Description: Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630).
Study NCT02085291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine infusion to titrate MAP to usual level
Study NCT02085291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid
Description: Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
Study NCT00814957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334
Description: D3 receptor antagonist
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 100 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 200 mg oral solution, single dose
Study NCT03609372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The STOP-HPV Trial 6: Maintenance
Description: In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
Study NCT02083458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization of the axillary vein.
Study NCT01677247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
Study NCT01677247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
Study NCT03742349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion
Study NCT03742349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
Study NCT03742349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: Capsule
Study NCT03742349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capmatinib
Description: Tablet
Study NCT03742349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion
Study NCT03742349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: LIVI (Liquid in vial) Solution for injection
Study NCT01409720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: tailored isometric physical exercise
Study NCT00493038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
Study NCT00493038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate
Description: Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
Study NCT03692858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block plus IPACK Block
Description: Adductor Canal Block plus IPACK Block using Ropivacaine
Study NCT03692858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Adductor Canal Block using Ropivacaine
Study NCT03537391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body contrast enhanced computer tomography
Description: Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
Study NCT03537391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTC-HMDP planar bone scintigraphy (BS)
Description: Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
Study NCT03537391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-HMDP single photon emission computer tomography/computer tomography
Description: SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index \~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
Study NCT03537391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging
Description: Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
Study NCT03537391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography
Description: 18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (\<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is \< 6 mm.
Study NCT00564811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)
Description: Agaricus blazei powder, 10 grams/day, for 5 months
Study NCT02904980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical Training
Description: Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
Study NCT02904980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quiet Eye Training
Description: Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
Study NCT01028469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artelon MTP Spacer
Description: Metatarsophalangeal hemi-implant
Study NCT01460823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cochlear Implantation using image guided surgical techniques
Description: Percutaneous Cochlear Implantation using image guided surgical techniques.
Study NCT03442634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Hydration
Description: this group will start oral hydration within 1 hour after cesarean section
Study NCT03442634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Oral Hydration
Description: this group will start oral hydration 6 hours after cesarean section
Study NCT01851408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT01851408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT02776241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Study NCT03676127 — intervention group
Intervention type: OTHER
Intervention: ultrasonographic dermal thickness measurements
Description: ultrasonographic dermal thickness measurements
Study NCT00670410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Related donor transplant
Description: Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
Study NCT00670410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood transplant
Description: Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
Study NCT00670410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients > 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration > 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
Study NCT00670410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
Study NCT00670410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
Study NCT03720132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive flushing of the port catheter
Description: The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
Study NCT02441504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity Exercise
Description: aerobic exercise training using walking and running
Study NCT00356031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
Study NCT00356031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
Study NCT00356031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
Study NCT00305942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 4mg/m2 IV on days 1, 8.
Study NCT00305942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC=5 IV day 1 only .
Study NCT04575701 — intervention group
Intervention type: OTHER
Intervention: TNF Alpha therapy
Description: Retrospective analysis of outcome of first TNF Alpha therapy
Study NCT03317951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel integrated care concept (NICC)
Description: Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
Study NCT03317951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
Study NCT02312947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coblation (COBLATION II surgery system ,CE8001-01)
Description: comparison of two methods of operation : coblation and cold dissection
Study NCT02312947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold dissection adenoidectomy
Description: comparison of two methods of operation : coblation and cold dissectionby currete
Study NCT03147469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexion
Description: After changing the position of head and neck of subjects to flexion, the variables were measured.
Study NCT03147469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extension
Description: After changing the position of head and neck of subjects to extension, the variables were measured.
Study NCT03147469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right rotation
Description: After changing the position of head and neck of subjects to right flexion, the variables were measured.
Study NCT02100605 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phytosun, decongestant, nasal spray
Description: one time application of the nasal spray
Study NCT02100605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phytosun, decongestant, nasal spray
Description: one time application of the nasal spray
Study NCT03338660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Platelets
Description: Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
Study NCT03338660 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of Platelets
Description: Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
Study NCT03338660 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive infusion placebo (saline).
Study NCT02178722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: IV infusion
Study NCT02178722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: Oral daily dosing